←Return to Faculty Page

Krisztina M. Papp-Wallace, Ph.D.

Assistant Professor of Medicine, Case Western Reserve University

Division of Infectious Diseases & HIV Medicine

Research Service, Louis Stokes Cleveland VA Medical Center

Email : kmp12@case.edu
Office Phone : 216.791.3800 ext4608
Fax : 216.231.3482
Office : Cleveland VA Medical Center


  • B.S. : Baldwin-Wallace College
  • Ph.D. : Pharmacology, Case Western Reserve University School of Medicine

Research Interests

PenA β-lactamaseβ-Lactamase-mediated resistance by Gram-negative bacteria is major threat to modern medicine. Annually, the cases of β-lactam resistant Gram-negatives are slightly over 100,000 and account for over 3,200 deaths.

PenRA transcriptional regulatorOf these Gram-negatives, the Burkholderia cepacia complex is emerging as important group of drug-resistant pathogens and our understanding of these unique pathogens remains undeveloped.

The goal of our laboratory is to identify novel ways of overcoming β-lactamase-mediated resistance in B. cepacia complex and other Gram-negative pathogens.

Selected References

  • Papp-Wallace KM, Endimiani A, Taracila M, and Bonomo RA. (2011) "Carbapenems: past, present, and future." Antimicrobial Agents and Chemotherapy, Nov;55(11):4943-60.
  • Levitt PS, Papp-Wallace KM, Taracila MA, Hujer AM, Winkler ML, Smith KM, Xu Y, Harris ME, and Bonomo RA. (2012) “The Ω-loop of the class A carbapenemase KPC-2 contains evolutionary potential for ceftazidime,” Journal of Biological Chemistry, 287(38):31783-93.
  • Papp-Wallace KM, Taracila MA, Gatta JA, Ohuchi N, Bonomo RA, and Nukaga M. (2013) “Insights into β-lactamases from Burkholderia spp., two phylogenetically related yet distinct resistance determinants.” Journal of Biological Chemistry 288(26):19090-102.
  • Papp-Wallace KM, Winkler ML, Gatta JA, Taracila MA, Chilakala S, Xu Y, Johnson JK, Bonomo RA. (2014) “Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.” Antimicrobial Agents and Chemotherapy, 58(8):4290-7.
  • Papp-Wallace KM, Winkler ML, Taracila MA, Bonomo RA. (2015) Variants of the KPC-2 β-lactamase which are resistant to inhibition by avibactam. Antimicrobial Agents and Chemotherapy, pii: AAC.04406-14.